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Induction of Cardiac Angptl4 by Dietary Fatty Acids Is
Mediated by Peroxisome Proliferator-Activated Receptor
/ and Protects Against Fatty Acid–Induced
Oxidative Stress
Anastasia Georgiadi, Laeticia Lichtenstein, Tatjana Degenhardt, Mark V. Boekschoten,
Marc van Bilsen, Beatrice Desvergne, Michael Mu¨ller, Sander Kersten
Rationale: Although dietary fatty acids are a major fuel for the heart, little is known about the direct effects of
dietary fatty acids on gene regulation in the intact heart.
Objective: To study the effect of dietary fatty acids on cardiac gene expression and explore the functional
consequences.
Methods and Results: Oral administration of synthetic triglycerides composed of one single fatty acid altered
cardiac expression of numerous genes, many of which are involved in the oxidative stress response. The gene most
significantly and consistently upregulated by dietary fatty acids encoded Angiopoietin-like protein (Angptl)4, a
circulating inhibitor of lipoprotein lipase expressed by cardiomyocytes. Induction of Angptl4 by the fatty acid
linolenic acid was specifically abolished in peroxisome proliferator-activated receptor (PPAR)// and not
PPAR/ mice and was blunted on siRNA-mediated PPAR/ knockdown in cultured cardiomyocytes.
Consistent with these data, linolenic acid stimulated binding of PPAR/ but not PPAR to the Angptl4 gene.
Upregulation of Angptl4 resulted in decreased cardiac uptake of plasma triglyceride-derived fatty acids and
decreased fatty acid-induced oxidative stress and lipid peroxidation. In contrast, Angptl4 deletion led to
enhanced oxidative stress in the heart, both after an acute oral fat load and after prolonged high fat feeding.
Conclusions: Stimulation of cardiac Angptl4 gene expression by dietary fatty acids and via PPAR/ is part of a
feedback mechanism aimed at protecting the heart against lipid overload and consequently fatty acid–induced
oxidative stress. (Circ Res. 2010;106:1712-1721.)
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Cardiac contractility is dependent on the adequate deliveryof oxygen and energy substrates to the heart followed by
their efficient metabolic degradation to yield ATP. The
energy requirements of the contracting heart are primarily
met by fatty acid oxidation, with the remainder of energy
coming from glucose and lactate.1,2 Although fatty acids are
thus of major importance to the heart, excessive uptake of
fatty acids causes lipid overload or lipotoxicity and may
compromise cardiac function, possibly leading to cardiomy-
opathy.3 Consequently, cardiac uptake of fatty acids needs to
be well adjusted to fatty acid utilization. Because most of the
fatty acids taken up by the heart are derived from lipoprotein
lipase (LPL)-dependent hydrolysis of circulating triglyceride-
rich lipoproteins,4 the activity of LPL needs to be carefully
regulated via specific activators and inhibitors, especially
after a fatty meal.
Besides serving as a major fuel for the heart and a potential
lipotoxic substrate, fatty acids are able to regulate gene
expression.5 In vitro experiments in rat cardiomyocytes have
shown that fatty acids increase expression of uncoupling
protein 2, carnitine palmitoyltransferase 1, fatty acid trans-
porter Cd36, fatty acid binding protein 3, acyl-coenzyme
(Co)A synthetase long-chain family member 1, acyl-CoA
thioesterase, and long chain acyl-CoA dehydrogenase.6–9 As
these genes all represent target genes of peroxisome
proliferator-activated receptor (PPAR),10,11 they suggest an
important role of PPAR in fatty acid-dependent gene regu-
lation in the heart.12 However, little is known about the direct
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effects of dietary fatty acids on gene expression in the intact
heart. In addition, it is unclear what pathways are activated by
fatty acids besides their own catabolism.
Here we studied the comprehensive effects of dietary fatty
acids on cardiac gene expression in vivo by giving mice a
single oral bolus of synthetic triglyceride composed entirely
of one single fatty acid, which were either linolenic acid
(C18:3), linoleic acid (C18:2) or oleic acid (C18:1). Subse-
quent microarrays analysis yielded Angptl4 as the gene most
highly induced in the heart after oral fat administration. The
collective data suggest that induction of Angptl4 by dietary
fatty acids is mediated by PPAR/ and is part of a feedback
mechanism aimed at protecting cardiomyocytes against lipid
overload and consequently fatty acid–induced oxidative
stress, eg, lipotoxicity.
Methods
Materials
GW501516 was purchased from Alexis (Axxora, Raamsdonkveer, The
Netherlands). Wy14643 was obtained from Eagle Picher Technologies
laboratories (Lenexa, Kan). Trilinolein (9c,12c) and trilinolein
(9c,12c,15c) were from Larodan Free Chemicals (Malmo, Sweden).
SYBR green was from Eurogentec (Seraing, Belgium), and all other
chemicals were from Sigma (Zwijndrecht, The Netherlands).
Animals
Pure-bred Sv129 PPAR/ mice (129S4/SvJae) and corresponding
wild-type mice (129S1/SvImJ) were purchased from Jackson Labo-
ratory (Bar Harbor, Maine). The Angptl4/ and transgenic mice
were on C57Bl/6 background and have been previously de-
scribed.13,14 The PPAR// mice were on a mixed background
(Sv129/C57Bl/6) and have been previously described.15 Males mice
were used at 2.5 to 4 months of age.
Mice were anesthetized with a mixture of isoflurane (1,5%),
nitrous oxide (70%), and oxygen (30%). Blood was collected via
orbital puncture into EDTA tubes. After euthanasia, the hearts were
excised and stored in 80°C. The animal studies were approved by
Animal Ethics Committee of Wageningen University and the Uni-
versity of Lausanne, Switzerland.
Oral Lipid Load
Starting at 5:00 AM, the animals were fasted for 4 hours, followed by
an intragastric gavage of 400 L of synthetic triglyceride (triolein,
trilinolein, and trilinolein). The control group received only car-
boxymethylcellulose (CMC). The mice were killed 6 hours thereaf-
ter. Four to 5 mice per group were used.
High-Fat Diet
Angptl4/, /, and transgenic mice on C57Bl/6 background
received a low-fat diet (LFD) or high-fat diet (HFD) for 8 weeks,
providing 10 or 45 energy percent in the form of triglycerides,
respectively (D12450B or D12451, Research Diets, New Bruns-
wick). The major source of fat in the diet was palm oil, with 5 energy
percent provided as soybean oil.
Cell Culture
Neonatal cardiomyocytes were isolated and cultured as described using
differential plating to separate myocytes from nonmyocytes.16 The
experiments were approved by the Animal Ethics Committee of Maas-
tricht University. Neonatal cardiomyocytes were incubated with
1 mol/L GW501516 or 62.5 mol/L, 125 mol/L, or 250 mol/L
linolenic for 6 hours as previously described.17 In a second experiment,
cardiomyocytes were incubated with 1 mol/L GW501516, 10 mol/L
Wy14643, or 250 mol/L linolenic acid for 24 hours.
Plasma Lipid Parameters
Plasma was obtained from blood by centrifugation for 10 minutes at
10,000 g. The plasma free fatty acids and triglyceride concentration
were determined using kits from Instruchemie (Delfzijl, The Netherlands).
An expanded Methods section is available in the Online Data
Supplement at http://circres.ahajournals.org.
Results
Dietary Fatty Acids Have a Major Impact on
Cardiac Gene Expression
To study the acute effects of dietary fatty acids on cardiac gene
expression in vivo, SV129 mice were given a single oral gavage
of synthetic TGs composed entirely of either C18:1, C18:2, or
C18:3,18 thus mimicking a postprandial lipid challenge. Animals
receiving carboxymethylcellulose were used as control to study
the absolute effect of dietary fatty acids. Expression profiling
was carried out on individual mouse hearts collected 6 hours
after the gavage using Affymetrix Mouse Genome 430 2.0
Arrays. Pathway analysis using Ingenuity revealed that the
dominant pathway affected by the oral fat load was nuclear
factor-like 2 (Nrf2)-related oxidative stress, indicating that the
fatty acids induced oxidative stress (Online Figure I). This was
supported by examination of the top 20 of upregulated genes,
most of which were involved in the oxidative stress response,
including uncoupling protein 3 (Ucp3), heme oxygenase 1
(Hmox1), FK506 binding protein 5 (Fkbp5), lipocalin 2 (Lcn2),
glutathione S-transferase A3 (Gsta3),and metallothionein 2
(Mt2) (Figure 1). A large correspondence in gene regulation
between the fatty acids was observed, especially between C18:2
and C18:3. Indeed, scatter plot analysis indicated that the effects
of C18:2 and C18:3 on cardiac gene expression were remarkably
similar, whereas effects of C18:1 were somewhat different
(Online Figure II). Therefore, the remainder of the present article
focuses on effects of C18:3.
Apart from genes involved in the oxidative stress response,
various genes involved in lipid metabolism were also induced
by the fatty acids. Interestingly, the gene most significantly
and consistently upregulated by each of the dietary fatty acids
was Angptl4 (Figure 1), which encodes a secreted protein
Non-standard Abbreviations and Acronyms
4HNE 4-hydroxynonenal
Angptl4 angiopoietin-like protein 4
ChIP chromatin immunoprecipitation
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PPAR peroxisome proliferator-activated receptor
PPRE peroxisome proliferator-activated receptor response element
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involved in the regulation of plasma triglyceride levels.
Previous studies have shown that Angptl4 potently inhibits
LPL and accordingly plasma triglyceride clearance by con-
verting active LPL-dimers into inactive LPL-monomers.19–21
Although Angptl4 is known to be expressed in heart,22,23
the specific cardiac cell types that produce Angptl4 remain
unclear. Accordingly, we performed immunohistological
staining of Angptl4 in human heart samples. The results
reveal the presence of Angptl4 protein in cardiomyocytes and
vascular smooth muscle cells but not endothelial cells and
fibroblasts (Figure 2A). Significant production of Angptl4 by
cardiomyocytes was confirmed by the relatively low Ct
values for amplification of Angptl4 cDNA from rat cardio-
myocytes (Ct 22 to 23, data not shown).
Regulation of Angptl4 by Dietary PUFA Is
Entirely Mediated by PPAR/
Long-chain fatty acids are bona fide ligands for PPARs. The
previous demonstration that Angptl4 is a direct PPAR target
gene prompted us to investigate the role of PPARs in Angptl4
gene regulation by dietary fatty acids. We first determined the
relative expression of PPARs in mouse heart. All three PPAR
Figure 1. Cardiac Angptl4 expression is
highly sensitive to dietary fatty acids. Top
20 of genes upregulated after oral gavage
of synthetic triglyceride composed of
either linolenic acid (C18:3), linoleic acid
(C18:2), or oleic acid (C18:1). The heat
maps were generated directly from the
GCRMA normalized microarray data.
Genes are ranked according to mean fold
change with wild-type mice receiving
CMC serving as control. Only probe sets
showing significant upregulation by the
different fatty acids were included in the
analysis (P0.05).
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isotypes were well expressed in heart, with expression of
PPAR and PPAR/ being 50% of PPAR (Figure 2B).
In cultured neonatal rat cardiomyocytes, expression of
PPAR was markedly lower compared to both PPAR and
PPAR/ (Figure 2B). Because PPAR appears to be rather
insensitive to (dietary) fatty acids,24 we focused our studies
on PPAR and PPAR/. PPAR/ mice, PPAR//
mice, and the corresponding wild-type mice were given an
oral gavage of C18:3 as synthetic TG. Hearts were collected
6 hours thereafter for analysis of gene expression by quanti-
tative PCR. Remarkably, upregulation of Angptl4 by C18:3
was entirely abolished in the PPAR// mice, whereas it
was retained in the PPAR/ mice (Figure 3A). In contrast,
upregulation of Ucp3, another well-characterized PPAR tar-
get gene, was retained in PPAR// mice and completely
abolished in PPAR/ mice (Figure 3B). No compensatory
increase in PPAR/ and PPAR expression was observed in
PPAR/ and PPAR// mice, respectively (Online
Figure IV).
To examine whether regulation of Angptl4 by PPAR/
and not PPAR was supported by binding of PPAR/ to the
Angptl4 gene, we performed chromatin immunoprecipitation
(ChIP). Previously, we located the response element respon-
sible for PPAR-mediated upregulation to intron 3 of the
Angptl4 gene.25 Consistent with data on Angptl4 gene regu-
lation, ChIP on hearts of wild-type mice six hours after oral
gavage of C18:3 showed enhanced binding of PPAR/ but
not PPAR to the intronic PPRE (Figure 3C).
Nuclear receptors and other transcription factors bound to
such distal sites likely contact the basal transcription machin-
ery via DNA looping, and accordingly binding of PPAR to
distant PPREs can be demonstrated by showing cross-linking
of PPAR to the transcriptional start site (TSS).26,27 Indeed,
oral gavage of C18:3 enhanced binding of PPAR/ but not
PPAR to TSS of the Angptl4 gene (Figure 3D), whereas
C18:3 enhanced binding of PPAR but not PPAR/ to the
TSS of the Ucp3 gene (Figure 3E). No binding of either
PPAR or PPAR/ to the negative control gene Rplp0 was
observed (Figure 3F). These results demonstrate that the
induction of cardiac Angptl4 gene expression by dietary
C18:3 is mediated by PPAR/.
The fatty acid- and PPAR/-mediated induction of car-
diac Angptl4 expression likely occurred in cardiomyocytes,
as treatment of rat neonatal cardiomyocytes for 6 hours with
C18:3 dose-dependently increased Angptl4 mRNA, which at
the highest concentration was equivalent to that obtained
using GW501516 (Figure 3G). To further investigate the
specific role of PPAR/ in Angptl4 upregulation by fatty
acids in cardiomyocytes, we knocked-down PPAR or
PPAR/ in the cardiomyocyte cell line H9c2, which ex-
presses both receptors, using siRNA and studied the effect on
Angptl4 gene induction by C18:3 (Figure 3H). We observed
that knock-down of PPAR/ almost entirely abolished the
induction of Angptl4 gene expression by C18:3, whereas
knock-down of PPAR had little to no effect (Figure 3I).
Our results do not imply that Angptl4 is an exclusive target
gene of PPAR/ under any type of circumstances. Indeed,
we find that in rat neonatal cardiomyocytes, Angptl4 is
induced to a similar extent by synthetic PPAR and
PPAR/ agonists, as are other cardiac PPAR targets such as
Acsl1 and Acox1 (Figure 3J). Instead, our data suggest that
the stimulatory effect of dietary fatty acids on cardiac
Angptl4 expression is mediated specifically by PPAR/.
Induction of Angptl4 Protects Against Fatty
Acid–Induced Oxidative Stress
To study the effect of Angptl4 on the metabolic response to
dietary fat, we performed the oral fat load with C18:3
triglyceride in wild-type, Angptl4/ and Angptl4 transgenic
(Angptl4-Tg) mice. In agreement with inhibition of LPL by
Figure 2. Angptl4 protein localizes specifically to the cardio-
myocytes and not to endothelial cells. A, High-magnification
image (200) of the human heart tissue stained with an anti-
body against Angptl4 (bottom) or negative control (top).
Arrows point to endothelial cells (EC), vascular smooth muscle
cells (VSM), and cardiomyocytes (CM). Inset, The antibody used
specifically recognizes human Angptl4. HEK293 cells were
transfected with an expression vector encoding hAngptl4 and
the medium was collected and used for immunoblotting. The
protein recognizes the C-terminal portion of Angptl4 generated
by endogenous proteolytic cleavage. B, mRNA expression of
the 3 PPARs in adult mouse heart and rat neonatal cardiomyo-
cytes as determined by quantitative PCR. Error bars represent
SEM. A standard curve was included to confirm an amplification
efficiency of 1002% for all PPARs (Online Figure III). PPAR
expression was calculated as 1/[2^(CtPPARCt18S)], allowing
for direct comparison between the PPAR isotypes.
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Angptl4, the postprandial increase in plasma triglyceride was
dramatically increased in Angptl4-Tg mice, whereas it was
entirely blunted in Angptl4/ mice (Figure 4A). Consistent
with LPL inhibition, Angptl4 overexpression markedly re-
duced cardiac fatty acid uptake from [3H]triolein-labeled
very-low-density lipoprotein (VLDL)-like particles (Figure
4B). These results suggest that upregulation of Angptl4 by
dietary fatty acids will lead to reduced cardiac uptake of fatty
acids via inhibition of LPL, thereby suppressing the stimulus
that led to induction of Angptl4 expression.
To examine whether the inhibitory effect of Angptl4 on
cardiac fatty acid uptake is associated with reduced fatty
acid-induced oxidative stress, expression of Fkbp5, Lcn2, and
Gsta3 was determined 6 hours after oral gavage with either
control treatment (CMC) or C18:3 triglyceride in wild-type,
Angptl4/ and Angptl4-Tg mice. All three genes represent
markers of oxidative stress.28–30 Consistent with a protective
role of Angptl4 against fatty acid-induced oxidative stress,
the magnitude of induction of Fkbp5, Lcn2, and Gsta3 by
C18:3 was dependent on Angptl4 genotype and inversely
correlated with Angptl4 expression (Figure 5A and 5B).
Expression of Fkbp5, Lcn2, and Gsta3 after the oral fat load
was not related to plasma free fatty acid (FFA) levels, which
followed an opposite pattern (Figure 5C). Expression of the
Figure 3. PPAR/ but not PPAR mediates the induction of Angtpl4 expression by dietary linolenic acid. Wild-type, PPAR/, and
PPAR// mice were given a single oral gavage of 0.5% CMC (open bars) or synthetic triglycerides composed entirely of C18:3
(closed bars). mRNA expression levels of Angptl4 (A) and Ucp3 (B) were determined in mouse heart using real-time PCR. Results are
expressed as fold change compared to the wild-type control mice. C through F, ChIP was performed on hearts of wild-type mice
given an oral gavage of either CMC or C18:3. Chromatin was precipitated using antibodies against PPAR or PPAR/. Rabbit IgG
was used as a specificity control. Real-time quantitative PCR was performed on reverse–cross-linked chromatin templates using prim-
ers specific to the known PPRE in intron 3 of the Angptl4 gene (C), the TSS of Angptl4 (D), the TSS of Ucp3 (E), and the negative con-
trol gene RpLp0 (F). G, Angptl4 expression in rat neonatal cardiomyocytes incubated with increasing concentrations of linolenic acid (0,
62.5, 125, and 250 mol/L) or GW501516 (1 mol/L) for 6 hours. H, Expression of PPAR and PPAR/ in H9c2 cardiomyocytes trans-
fected with siRNA against PPAR and PPAR/. I, Fold induction of Angptl4 expression by 6 hours of linolenic acid treatment
(250 mol/L) in H9c2 cardiomyocytes transfected with siRNA against PPAR and PPAR/. J, Expression of Angptl4 and known PPAR
targets Acsl1 and Acox1 in rat neonatal cardiomyocytes incubated for 24 hours with linolenic acid (250 mol/L), GW501516 (1 mol/L),
or Wy14643 (10 mol/L). Error bars represent SEM. Statistical significance was determined with a Student’s t test (P0.05).
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endoplasmic reticulum stress marker Herpud1 mimicked the
pattern of oxidative stress markers (Figure 5A).
Finally, we examined whether Angptl4 may exert a similar
effect in the context of a chronic fat overload. To that end, we
measured expression of the oxidative stress markers and
performed immunohistochemical and quantitative analysis of
4-HNE protein adducts in wild-type and Angptl4/ mice fed
a HFD for 8 weeks. 4-HNE is one of the major biologically
active aldehydes formed during inflammation and oxidative
stress. Formation of 4-HNE protein adducts is a marker for
lipid peroxidation.
Although high fat feeding did not influence expression
levels of Fkbp5, Lcn2 and Gsta3, expression was signifi-
cantly higher in Angptl4/ mice fed HFD compared to
wild-type mice fed HFD (Figure 6A). A similar trend was
observed for Herpud1. Furthermore, lipid peroxidation was
increased in Angptl4/ mice fed HFD, as shown by en-
hanced 4-HNE staining (Figure 6B). These results were
supported by quantitative analysis of 4HNE protein adducts
(Figure 6C) and MDA adducts (Figure 6D), which were
significantly increased in Angptl4/ mice fed HFD com-
pared to wild-type mice fed HFD. These data indicate that
Angptl4 protects against oxidative stress in the context of a
chronic fat overload. No differences in cardiac triglyceride
levels were observed between wild-type and Angptl4/
mice (Figure 6E).
Discussion
In the present article we show that the gene most significantly
and consistently upregulated by short term treatment with
dietary fatty acids is Angptl4. Induction of Angptl4 by dietary
fatty acids is mediated by PPAR/ and confers a protective
effect against fatty acid-induced oxidative stress by restrict-
ing cardiac fatty acid uptake via inhibition of LPL. Overall,
our data suggest that upregulation of Angptl4 by fatty acids is
part of a feedback mechanism aimed at preventing myocar-
dial fatty acid accumulation, thereby minimizing lipid-
induced oxidative stress and lipotoxicity (Figure 7). Although
our follow-up studies only included linolenic acid, the results
are likely generalizable to other dietary fatty acids.
Lipotoxicity describes the untoward consequences of fat
overload in a particular tissue and may be related to fatty
acid-induced oxidative stress, accumulation of lipotoxic in-
termediates such as ceramides and fatty acyl-CoA, and excess
storage of triglycerides.31 Chronic lipotoxicity in the heart has
Figure 4. Angptl4 overexpression raises postprandial plasma
triglyceride levels and decreases cardiac fatty acid uptake. A,
Wild-type (gray squares), Angptl4/ (open squares), and
Angptl4-Tg (black squares) mice were given a single oral
gavage of synthetic triglyceride (TG) composed entirely of
C18:3. Plasma triglyceride were determined in blood collected
via the tail vein. B, [3H]-labeled triolein was incorporated into
VLDL-like emulsion particles and directly injected into the tail
vein of wild-type and Angptl4-Tg mice. The heart was collected
30 minutes after the injection for determination of radioactivity.
*Significantly different between wild-type and Angptl4-Tg mice
according to Student’s t test (P0.05). Error bars represent
SEM.
Figure 5. Markers of oxidative stress are inversely correlated with Angptl4 expression after oral fat load. Wild-type, Angptl4/, and
Angptl4-Tg mice were given a single oral gavage of 0.5% CMC (open bars) or synthetic triglyceride composed entirely of C18:3
(closed bars). Mice were euthanized 6 hours later. A, mRNA expression levels of oxidative stress genes Fkbp5, Lcn2, and Gsta3 and
endoplasmic reticulum stress marker gene Herpud1, as determined by real-time PCR. B, mRNA expression levels of Angptl4. C,
Plasma levels of FFA and TG. Differences were evaluated statistically using two-way ANOVA. Significance (probability value) of effect of
genotype (G), treatment (T), and interaction (I) between genotype and treatment is indicated in each graph. n.s. indicates nonsignificant.
Error bars represent SEM.
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been shown to promote cardiomyopathy in several animal
models.12,32–34 Most of these models are characterized by a
mismatch between myocardial fatty acid uptake and utiliza-
tion, as in mice with heart-specific overexpression of acyl-
CoA synthetase, fatty acid transport protein 1, or lipoprotein
lipase.32–34 Although triglycerides are unlikely to be the
actual culprit in cardiac lipotoxicity, they may be guilty by
association as its levels may be positively correlated with
lipotoxic intermediates. However, we did not see increased
cardiac triglyceride levels in Angptl4/ mice compared to
wild-type mice after 8 weeks of high fat feeding, suggesting
that the increase in fatty acid uptake is limited or that the
incoming fatty acids are efficiently oxidized. In the present
study, it was not possible to investigate the effect of Angptl4
deletion on cardiac lipid storage, oxidative stress, and param-
eters of cardiac dysfunction after a more prolonged period of
HFD, as a cachectic phenotype progressively emerges after
12 weeks of HFD (L.L. et al, manuscript in preparation).
In a previous study, heart-specific Angptl4 overexpression
reduced cardiac LPL activity and reversed the excessive lipid
storage in hearts of lipotoxic acyl-CoA synthetase transgenic
mice.22 In agreement with these data, we find that Angptl4
overexpression reduced cardiac fatty acid uptake and protects
against fatty acid-induced oxidative stress. In contrast, An-
gptl4 deletion aggravated oxidative stress both acutely and
after chronic HFD. Because we used whole body Angptl4
overexpression and deletion models, strictly we cannot rule
out that the observed effects may be related to changes in
extracardiac Angptl4 expression. However, the current liter-
ature mainly supports a paracrine function of Angptl4, and
the role of Angptl4 as endocrine factor remains somewhat
uncertain.
Angptl4 was discovered by screening for target genes of
PPAR and PPAR in liver and adipose tissue, respec-
tively.35,36 It is member of a family of angiopoietins and
angiopoietin-like proteins and is produced by a variety of
organs. Numerous studies using Angptl4 transgenic or knock-
out mice have invariably shown a stimulatory effect of
Angptl4 on plasma triglyceride levels, which is achieved by
inhibiting LPL activity.13,14,19,22,37–40 These data have estab-
lished Angptl4 as an important regulator of plasma triglycer-
ide levels. The present data suggest that Angptl4 is upregu-
lated by dietary fatty acids to inhibit local LPL activity and
consequently reduce fatty acid uptake and lipid-induced
oxidative stress.
To study the role of PPARs in cardiac gene regulation by
dietary fatty acids, we ideally should have used cardiomyo-
cyte-specific PPAR/ mice but unfortunately we did not
have access to these animals. The PPAR-dependent upregu-
lation of Angptl4 and Ucp3 by dietary linolenic acid under-
scores the importance of TG-rich lipoproteins as source of
PPAR ligands in the heart, which are liberated via LPL.41,42
Figure 6. Angptl4 protects against oxidative stress in the context of chronic fat overload. A, Wild-type and Angptl4/ mice were fed a
LFD or HFD for 8 weeks. Expression levels of Fkbp5, Lcn2, Gsta3, and Herpud1 in the heart were measured by real-time PCR. Results
are expressed as fold change compared to wild-type mice on LFD. B, Immunohistochemistry of 4-HNE protein adducts in mouse car-
diac tissue from mice fed HFD for 8 weeks. Representative sections are shown. Magnification, 400. Right, Negative control obtained
using rabbit serum. Quantitative measurement of 4HNE protein adducts (C) and MDA adducts (D). E, Cardiac triglyceride content. Gray
bars indicate wild-type mice; black bars, Angptl4/ mice. *Significantly different between wild-type and Angptl4/ mice according to
Student’s t test (P0.05). Error bars represent SEM.
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Remarkably, upregulation of Angptl4 by C18:3 in intact heart
and cultured cardiomyocytes was entirely mediated by
PPAR/ and not PPAR. These data were supported by
ChIP data showing C18:3-induced binding of PPAR/ and
not PPAR to the Angptl4 gene in the intact heart. Because
we did not study PPAR, strictly we cannot rule out a role for
PPAR in mediating the effect of (dietary) fatty acids on
cardiac Angptl4 expression. However, as similar results were
obtained in cultured cardiomyocytes, which express little
PPAR, the data favor a specific role of PPAR/ in the
regulation of cardiac Angptl4 by C18:3. It is unclear what
mechanism may underlie the differential role of PPAR/
versus PPAR in mediating induction of Angptl4 and Ucp3
by C18:3, respectively. Induction of Ucp3 by linoleic acid via
PPAR rules out a PPAR/-specific ligand activity that is
generated by linolenic acid in heart. Gel shift and transacti-
vation studies have failed to provide convincing evidence for
the existence of response elements or promoters that are
specifically or selectively bound or regulated by a particular
PPAR isotype.43,44 Indeed, in vitro experiments have revealed
that all three PPARs are intrinsically able to (trans)activate
the human and mouse Angptl4 gene.25 However, the situation
may be different in vivo in the absence of PPAR overexpres-
sion or when PPARs are activated via endogenous ligands
rather than via high-affinity synthetic agonists. Thus, the
dominant receptor in the regulation of a particular PPAR
target is likely context- and tissue-dependent and additionally
depends on whether PPAR is activated via endogenous or
synthetic agonists. When as in cardiomyocytes two or more
PPARs are expressed in the same cell and are simultaneously
activated, it is possible that specific binding of one PPAR
isotype to a particular PPRE is promoted via interactions with
another protein that binds adjacent to the PPRE and is
expressed in a tissue-specific manner. In this context, it is
interesting to mention that recent genome wide profiling of
PPAR and PPAR binding sites revealed colocalization of
PPAR binding with other transcription factor binding sites
and demonstrated interplay between PPARs and other tran-
scription factors in PPAR-mediated gene regulation.45–47
Recently, targeted PPAR/ overexpression in the heart
was shown to have a clear differential effect on cardiac
metabolism compared to PPAR overexpression.48 In con-
trast to PPAR, PPAR/ overexpression did not impact
fatty acid transport and failed to induce myocardial lipid
accumulation. Based on the data presented here it can be
hypothesized that PPAR/ is neutral toward cardiac lipid
storage by inducing Angptl4 expression, which in turn feeds
back on fatty acid uptake.
Multiple studies support an effect of Angptl4 on endothe-
lial function, mostly pointing to an antiangiogenic activity of
Angptl4.49–51 Our immunohistochemical results indicate that
Angptl4 is absent from vascular endothelial cells in the heart,
whereas it is abundantly present in cardiomyocytes. These
data are in line with previous studies showing that Angptl4 is
absent from a number of different endothelial cells, yet is
dramatically induced under hypoxic conditions.50 Hypoxia
also upregulates Angptl4 in cardiomyocytes.52 Induction of
Angptl4 by hypoxia and the associated inhibition of fatty acid
uptake may be an adaptive mechanism to shift fuel use
toward glucose, which requires less oxygen for oxidation.
In conclusion, our data show that an acute oral load of
triglycerides stimulates an oxidative stress response in the
heart. The concomitant upregulation of Angptl4 by dietary
fatty acids is mediated by PPAR/ and is part of a feedback
mechanism aimed at protecting the heart against lipid over-
load and consequently fatty acid–induced oxidative stress,
one of the hallmarks of lipotoxic cardiomyopathy.
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Novelty and Significance
What Is Known?
● Little is known about the impact of dietary fat on gene expression in
the heart.
● Peroxisome proliferator-activated receptors (PPARs) mediate the
effects of fatty acids on gene expression in several tissues.
● The secreted protein angiopoietin-like protein (Angptl)4 is an inhibitor
of plasma triglyceride hydrolysis.
What New Information Does This Article Contribute?
● Dietary fat induces the expression of Angptl4 in the heart.
● Induction Angptl4 by fat is mediated by PPAR/, and it protects the
heart against lipid overload and oxidative stress.
Dietary fat is the major fuel for the heart, but little is known
about its impact on the expression of cardiac genes. We
studied, for the first time, the effect of specific fatty acids on
whole genome expression in the heart. We found that the
gene most highly induced by dietary fat was Angptl4. This
gene codes for a secreted inhibitor of plasma triglyceride
hydrolysis. Angptl4 was found to be produced by cardiomyo-
cytes, and its induction by fat was mediated by the tran-
scription factor PPAR/, but not PPAR. Induction of
Angptl4 was associated with a decrease in lipid uptake from
the blood. Myocardial lipid overload and oxidative stress were
also decreased. These findings suggest that Angtl4 is a major
modulator of fat uptake in the heart and that it participates in
a novel feedback mechanism that involves PPAR/. Angptl4
protects the heart against lipid overload and fatty acid–
induced oxidative stress after ingestion of dietary fat.
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